The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Howard A. Burris

The Sarah Cannon Research Institute

250 25th Avenue North

Suite 110

Nashville

USA

[email]@tnonc.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • The Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, USA. 2004 - 2011
  • Sarah Cannon Cancer Center, Nashville, TN 37203, USA. 2006

References

  1. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Burris, H.A., Jones, S.F., Williams, D.D., Kathman, S.J., Hodge, J.P., Pandite, L., Ho, P.T., Boerner, S.A., Lorusso, P. Invest. New. Drugs (2011) [Pubmed]
  2. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Burris, H., Rocha-Lima, C. Oncologist (2008) [Pubmed]
  3. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?. Burris, H.A. Semin. Oncol. (2006) [Pubmed]
  4. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Burris, H.A., Rivkin, S., Reynolds, R., Harris, J., Wax, A., Gerstein, H., Mettinger, K.L., Staddon, A. Oncologist (2005) [Pubmed]
  5. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. Burris, H.A., Hurwitz, H.I., Dees, E.C., Dowlati, A., Blackwell, K.L., O'Neil, B., Marcom, P.K., Ellis, M.J., Overmoyer, B., Jones, S.F., Harris, J.L., Smith, D.A., Koch, K.M., Stead, A., Mangum, S., Spector, N.L. J. Clin. Oncol. (2005) [Pubmed]
  6. Recent updates on the role of chemotherapy in pancreatic cancer. Burris, H.A. Semin. Oncol. (2005) [Pubmed]
  7. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. Burris, H., Yardley, D., Jones, S., Houston, G., Broome, C., Thompson, D., Greco, F.A., White, M., Hainsworth, J. J. Clin. Oncol. (2004) [Pubmed]
  8. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Burris, H.A. Oncologist (2004) [Pubmed]
 
WikiGenes - Universities